Daiichi Sankyo posts 'extraordinary loss' of nearly $1B

May 8, 2026 01:16 PM EDT PharmaManufacturing Dai­ichi Sankyo posts 'ex­tra­or­di­nary loss' of near­ly $1B af­ter over­es­ti­mat­ing need for ADC ca­pac­i­ty Anna Brown News Reporter Dai­ichi Sankyo is scrap­ping plans to build an­ti­body-drug con­ju­gate man­u­fac­tur­ing ca­pac­i­ty and record­ed an “ex­tra­or­di­nary loss” of 149.4 bil­lion Japan­ese yen ($950 mil­lion) af­ter over­promis­ing … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER